ACADIA PHARMACEUTICALS INC. Debt Securities, Available-for-sale, Unrealized Loss Position
ACADIA PHARMACEUTICALS INC. (ACAD) had Debt Securities, Available-for-sale, Unrealized Loss Position of $440.24 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $440.24M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $271.48M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $91.80M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $133.49M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $440.24M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $271.48M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $91.80M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $133.49M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $203.37M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $62.20M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $84.39M 10-K · filed 2026-02-26 |
| 2024-09-30 | $47.94M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $314.17M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $222.49M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $149.95M 10-K · filed 2025-02-27 |
| 2023-09-30 | $210.20M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $242.84M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $95.14M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $230.17M 10-K · filed 2024-02-28 |
| 2022-09-30 | $258.25M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $270.87M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $238.68M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $291.00M 10-K · filed 2023-02-28 |
| 2020-12-31 | $169.35M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |